MedTrace Logo

Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination

NCT04143412 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2020-01-18

No results posted yet for this study

Summary

The aim of our work is to compare the antiproteinuric efficacy of ACEI monotherapy, Selective MRA monotherapy and their combination in mildly hypertensive patients with type 2 diabetes mellitus and microalbuminuria

Conditions

  • Diabetic Nephropathy Type 2
  • Microalbuminuria Due to Type 2 Diabetes Mellitus

Interventions

DRUG

Tritace (Ramipril 10 mg)

Stratified randomized clinical trial

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Mostafa O El Mokadem, M.D. · Cardiology department,Faculty of Medicine, Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2020-02-29
Completion
2020-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143412 on ClinicalTrials.gov